The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.

Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB
J Am Soc Nephrol. 2009 20 (11): 2380-8

PMID: 19797472 · PMCID: PMC2799181 · DOI:10.1681/ASN.2008111138

Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists not only improve metabolic abnormalities of diabetes and consequent diabetic nephropathy, but they also protect against nondiabetic chronic kidney disease in experimental models. Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence. Increased local expression of PPAR-gamma paralleled these changes. Underlying mechanisms included increased expression of klotho, decreased systemic and renal oxidative stress, and decreased mitochondrial injury. Pioglitazone also regulated p66(Shc) phosphorylation, which integrates many signaling pathways that affect mitochondrial function and longevity, by reducing protein kinase C-beta. These results suggest that PPAR-gamma agonists may benefit aging-related renal injury by improving mitochondrial function.

MeSH Terms (11)

Age Factors Aging Animals Disease Progression Kidney Diseases Male Pioglitazone PPAR gamma Rats Rats, Sprague-Dawley Thiazolidinediones

Connections (2)

This publication is referenced by other Labnodes entities:

Links